Shortage of methylphenidate hydrochloride products is resolving

The overall supply of methylphenidate modified-release products affected by the global shortage that started in late 2024 continues to improve and stabilise. 

These products are used to treat attention deficit hyperactivity disorder. 

In summary: 

• The shortages of most methylphenidate modified-release products have resolved, including Concerta modified-release tablets and Ritalin LA modified-release capsules.
• The shortages of all strengths of Rubifen LA capsules are expected to resolve by the end of June 2026. 

We continue to monitor the supply of all methylphenidate products closely.

Please go to About the shortage of methylphenidate hydrochloride products for more information. 

You can also go to the Medicine Shortage Reports Database- external site- external site (search for ‘methylphenidate’) for the most up-to-date information.